Land: Australië
Taal: Engels
Bron: Department of Health (Therapeutic Goods Administration)
paracetamol, Quantity: 500 mg; codeine phosphate hemihydrate, Quantity: 10 mg; doxylamine succinate, Quantity: 5.1 mg
Soul Pattinson Manufacturing Pty Ltd
Tablet, uncoated
Excipient Ingredients: stearic acid; magnesium stearate; ethanol; microcrystalline cellulose; lactose monohydrate; maize starch; povidone; crospovidone
Oral
20, 24, 12, 36, 10, 30, 40
(S4) Prescription Only Medicine
For the temporary relief of acute moderate pain and fever.
Visual Identification: White capsule shaped, biconvex, bevel edged, uncoated tablet with breakline on one side and plain on the other side.; Container Type: Blister Pack; Container Material: PVC/PVDC/Al; Container Life Time: 36 Months; Container Temperature: Store below 30 degrees Celsius
Registered
2019-05-23
Product Information Medco Paracetamol 500, Codeine Phosphate 10 & Doxylamine Succinate 5.1 V1220 1 AUSTRALIAN PRODUCT INFORMATION - MEDCO PARACETAMOL 500, CODEINE PHOSPHATE 10 & DOXYLAMINE SUCCINATE 5.1 (PARACETAMOL, CODEINE PHOSPHATE HEMIHYDRATE & DOXYLAMINE SUCCINATE) WARNINGS _LIMITATIONS OF USE _ Because of the risks associated with the use of opioids, Medco Paracetamol 500, Codeine Phosphate 10 & Doxylamine Succinate 5.1 should only be used in patients for whom other treatment options, including non-opioid analgesics, are ineffective, not tolerated or otherwise inadequate to provide appropriate management of pain (see _section 4.4 Special Warnings _ _and Precautions for Use_). _HAZARDOUS AND HARMFUL USE _ Medco Paracetamol 500, Codeine Phosphate 10 & Doxylamine Succinate 5.1 poses risks of hazardous and harmful use which can lead to overdose and death. Assess the patient’s risk of hazardous and harmful use before prescribing and monitor the patient regularly during treatment (see _section 4.4. Special Warnings and Precautions for Use_). _LIFE THREATENING RESPIRATORY DEPRESSION _ Serious, life-threatening or fatal respiratory depression may occur with the use of Medco Paracetamol 500, Codeine Phosphate 10 & Doxylamine Succinate 5.1. Be aware of situations which increase the risk of respiratory depression, modify dosing in patients at risk and monitor patients closely, especially on initiation or following a dose increase (see _section 4.4 Special _ _Warnings and Precautions for Use_). _CONCOMITANT _ _USE _ _OF _ _BENZODIAZEPINES _ _AND _ _OTHER _ _CENTRAL _ _NERVOUS _ _SYSTEM _ _(CNS) _ _DEPRESSANTS, INCLUDING ALCOHOL _ Concomitant use of opioids with benzodiazepines, gabapentinoids, antihistamines, tricyclic antidepressants, antipsychotics, cannabis or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. Limit dosages and durations to the minimum required, and monitor patients for signs and symptoms of respiratory depre Lees het volledige document